Elzasonan

From Self-sufficiency
Revision as of 03:46, 5 April 2010 by El3ctr0nika (Talk)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Elzasonan
File:Elzasonan.png
Systematic (IUPAC) name
(E)-3-[3-[(4-ethylphenoxy)methyl]-4-methoxyphenyl]-1-(1-methyl-4-nitropyrazol-3-yl)prop-2-en-1-one
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 220322-05-4
ATC code none
PubChem CID 19544192
Chemical data
Formula C22H21FN4O
Molar mass 421.44582 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Elzasonan (CP-448,187) is a selective 5-HT1B and 5-HT1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy.[1][2][3][4][5] By preferentially blocking 5-HT1B and 5-HT1D autoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects.[3]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
Azapirones: Buspirone • Gepirone • Tandospirone; Others: Flesinoxan • Oxaflozane
H1 Antagonists
Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)

  1. ↑ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4. 
  2. ↑ Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge, UK: Cambridge University Press. 2008. ISBN 0-521-85702-3. 
  3. ↑ 3.0 3.1 "IngentaConnect 5-HT1 Receptor Augmentation Strategies as Enhanced Efficacy Thera..." 
  4. ↑ "Pfizer, Inc.: analysis of patenting 1998 – 2001; Expert Opinion on Therapeutic Patents - 12(5):Pages 725-732 - Informa Healthcare". 
  5. ↑ "Discontinued psychiatric drugs in 2008; Expert Opinion on Investigational Drugs - 18(10):Pages 1431-1443 - Informa Healthcare". 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Elzasonan&oldid=22794"